Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 823 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR How can we improve LGBTQ+ cancer care? – That Cancer Conversation June 27, 2023 Cancer in My Community: Overcoming Inequities in Care in Argentina January 3, 2023 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Surgery for Recurrent Ovarian Cancer Does Not Improve Survival December 10, 2019 Load more HOT NEWS Cómo prepararse para su exploración por TEP-TC 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... Prostate Cancer Genomics in Racial Minority Groups
